Search Medical Condition
Please enter condition
Please choose location from dropdown

Tlapan, Mexico Clinical Trials

A listing of Tlapan, Mexico clinical trials actively recruiting patients volunteers.

RESULTS

Found (223) clinical trials

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

OBJECTIVES: Primary - To determine the percentage of pathological responses in patients with stage II or III breast cancer treated with neoadjuvant therapy comprising fluorouracil, doxorubicin hydrochloride, and cyclophosphamide followed by trastuzumab (Herceptin®) and paclitaxel. - To compare the disease-free survival of patients treated with adjuvant therapy comprising trastuzumab versus ...

Phase

2.73 miles

Learn More »

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast ...

Phase

2.73 miles

Learn More »

PI Vs. NNRTI Based Therapy for HIV Advanced Disease

Current guidelines for initial therapy in HIV infection recommend 2 NRTIs plus either a ritonavir boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI). Recent data suggests that the rate of response to PI based therapy may be slightly compromised if the baseline CD4 count is ≤ 200/mm3 and ...

Phase

2.73 miles

Learn More »

Effect of the CAIPaDi Care Model in Relatives of Patients With Type 2 Diabetes Mellitus

Diabetes mellitus is one of the most challenging health issues of our time, the percentage of adults with this disease tripled in Mexico between 1993 and 2012; In 1993 the prevalence was 6.7% (cases previously diagnosed 4.6% and diagnosed during the survey 2.1%), whereas in 2012, the prevalence was 14.4% ...

Phase N/A

2.73 miles

Learn More »

Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis

Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant systems. This state is frequently associated with chronic diseases like obesity, insulin resistance, metabolic syndrome and hepatic steatosis. In the liver, the oxidative stress may trigger the progression of fatty liver disease, from triglyceride accumulation to inflammation, cirrhosis ...

Phase

2.73 miles

Learn More »

Validation of an Integrated Attention Model for Patients With Type 2 Diabetes

Background: There are major deficiencies in the attention quality provided to people with diabetes in Mexico. The percentage of compliance of therapeutic objectives is noticeably lower than the one informed in developed countries. It is required to have structured management strategies, adapted to traits of our population, which allow improving ...

Phase N/A

2.73 miles

Learn More »

Treatment of Hypoactive Delirium and Outcome Measures

Background Delirium is a cognitive disorder that affects attention and other mental functions. It has an acute onset (in hours or days), a fluctuating course and has various conditioning factors such as diseases or withdrawal or intoxication syndromes. Delirium is a syndrome with multifactorial origin, it commonly presents in elderly ...

Phase

2.73 miles

Learn More »

Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders

There are case reports and pilot studies in patients with primary biliary cholangitis (PBC) In the literature in which the effect of fibrates (specially bezafibrate) on the improvement of biochemical cholestasis have been seen, however the clinical benefit (survival, mortality, fatigue, pruritus) has not been reported and likewise the response ...

Phase

2.73 miles

Learn More »

Evaluation of Intestinal Permeability Expression of Genes of Epithelial Integrity in the Duodenal Wall Serum Inflammatory Cytokines and Lipopolysaccharide in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)

There is evidence that the non-selective beta-blocker (NSBB) propranolol reduces intestinal permeability and decreases bacterial translocation in cirrhotic patients, independent of hemodynamic effects on portal pressure. The mechanism by which this decrease in intestinal permeability and bacterial translocation occurs has not been established. Among the proposed mechanisms are: modification of ...

Phase N/A

2.73 miles

Learn More »